Biotech startup Spiderwort nabs $13.2m in Horizons-led Series A

Horizons Ventures led the round with participation from K5 Global, BoxOne Ventures and Break Off Capital.

  • Other investors in the round include the Capital Angel Network and Anges Québec
  • This investment will support Spiderwort’s transition from pre-clinical studies to the clinical trials
  • Spun out as a startup from the Pelling Lab, Spiderwort is led by CEO Charles M. Cuerrier

Toronto-based Spiderwort, a biotechnology company focused on treating acute spinal cord injuries, has raised $13.2 million in Series A financing. Horizons Ventures led the round with participation from K5 Global, BoxOne Ventures and Break Off Capital.

Other investors in the round include the Capital Angel Network and Anges Québec.

This investment will support Spiderwort’s transition from pre-clinical studies to the clinical trials.

“We are grateful for the trust and support from our funding partners and investors. We are looking forward to continuing our journey with them,” said Dr. Charles M. Cuerrier, CEO, Spiderwort, in a statement. “With the closing of this financing round, we are now in position to accelerate our product development program to bring CelluBridge and CelluJuve closer to patients.”

Spun out as a startup from the Pelling Lab, Spiderwort is led by CEO Charles M. Cuerrier.

Horizons Ventures was co-founded by Solina Chau and Debbie Chang in 2005.